Clin Infect Dis . Successful treatment of prolonged, severe COVID-19 lower respiratory tract disease in a B-cell ALL patient with an extended course of remdesivir and nirmatrelvir/ritonavir

[tetano]

Clin Infect Dis


. 2022 Nov 3;ciac868.
doi: 10.1093/cid/ciac868. Online ahead of print.
Successful treatment of prolonged, severe COVID-19 lower respiratory tract disease in a B-cell ALL patient with an extended course of remdesivir and nirmatrelvir/ritonavir


Emily S Ford ^{1 2} , William Simmons ¹ , Ellora N Karmarkar ¹ , Leah H Yoke ^{1 2} , Ayodale B Braimah ³ , Johnnie J Orozco ^{4 5} , Cristina M Ghiuzeli ^{4 6} , Serena Barnhill ⁷ , Coralynn L Sack ⁷ , Joshua O Benditt ⁷ , Pavitra Roychoudhury ^{2 8} , Alexander L Greninger ^{2 8} , Adrienne E Shapiro ^{1 2 9} , Jennifer L Hammond ¹⁰ , James M Rusnak ¹⁰ , Mikael Dolsten ¹⁰ , Michael Boeckh ^{1 2 4} , Catherine Liu ^{1 2 4} , Guang-Shing Cheng ^{2 4 7} , Lawrence Corey ^{1 2 4 8}



Affiliations

• PMID: 36326680
• DOI: 10.1093/cid/ciac868

Abstract

A patient with B-cell acute lymphoblastic leukemia (ALL) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had persistent, progressive pneumonia with viremia after 5 months of infection despite monoclonal antibodies, IV remdesivir and prolonged oral steroids. Twenty days of nirmatrelvir/ritonavir and 10 days of IV remdesivir led to full recovery.